In vitro antileishmanial activity of sustainable anacardic acid and cardol based silver nanoparticles on L. braziliensis
International Journal of Pharmaceutics, ISSN: 0378-5173, Vol: 619, Page: 121698
2022
- 7Citations
- 26Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations7
- Citation Indexes7
- CrossRef5
- Captures26
- Readers26
- 26
Article Description
The search for effective and less toxic drugs for the treatment of Cutaneous Leishmaniasis (CL) is desirable due to the emergence of resistant parasites. The present study shows the preparation, characterization and in vitro antileishmanial activity of green-based silver nanoparticles (AgNPs) with Cashew Nutshell Liquid (CNSL, main constituents: anacardic acid (AA) and cardol (CD). The synthesis of silver nanoparticles was achieved by reduction with sodium borohydride in the presence of anacardic acid or cardol under microwave irradiation (400 W, 60 °C, 5 min) resulting in AgAA and AgCD. In vitro assay showed opposite effects for AgAA and AgCD. While AgAA is highly toxic to macrophages (CC 50 = 6.910 µg mL −1 ) and almost non-toxic for L.braziliensis (IC 50 = 86.61 µg mL −1 ), AgCD results very selective toward killing the parasite (CC 50 = 195.0 µg mL −1, IC 50 = 11.54 µg mL −1 ). AA’s higher polarity and conical shape easily promote cell lysis by increasing cell permeability, while CD has a protective effect: for that reason, AA and AgAA were not further used for tests. CD (EC 50 = 2.906 µg mL −1 ) had higher ability to kill intracellular amastigotes than AgCD (EC 50 = 16.00 µg mL −1 ), however, less intact cells were seen on isolated CD tests. In addition, considering that NO is one of the critical molecular species for the intracellular control of Leishmania, we used Griess colorimetric test to analyze the effect of treatment with AgCD and CD. Overall, the in vitro antileishmanial tests indicate that AgCD should be further explored as a promising non-toxic treatment for CL.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0378517322002538; http://dx.doi.org/10.1016/j.ijpharm.2022.121698; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85127064855&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/35337904; https://linkinghub.elsevier.com/retrieve/pii/S0378517322002538; https://dx.doi.org/10.1016/j.ijpharm.2022.121698
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know